Table 1 Demographic characteristics and clinical scores
|  | HC (n = 45) | AFF (n = 22) | NON (n = 31) | P values | ||
|---|---|---|---|---|---|---|
HC vs AFF | AFF vs NON | HC vs NON | ||||
Age: median | 20.7 | 22.0 | 21.1 | 0.3141 |  > 0.9999 |  > 0.9999 |
Range [minimum, maximum] | [13.7, 37.0] | [13.2, 29.6] | [13.3, 26.8] | Â | Â | Â |
IQR | 18.3–22.7 | 19.4–26.1 | 19.6–22.8 |  |  |  |
Gender (%male/female) | 62/38 | 71/29 | 84/16 | 0.4280 | 0.4933 | 0.0702 |
Subject education: median (IQR) | 14 (12–15) | 12.5 (12–14.8) | 12 (11–13.3) |  > 0.9999 | 0.7141 | 0.0638 |
Parental education: median (IQR) | 15 (13–16) | 14 (12–17) | 15 (12.3–16) |  > 0.9999 |  > 0.9999 |  > 0.9999 |
SANS: median (IQR) | – | 7 (3–8) | 10 (6.3–12) | – | 0.0191 |  |
SAPS: median (IQR) | – | 2 (1–4.8) | 6 (3–8) | – | 0.0311 | – |
WASI: median (IQR) | 117 (110–120) | 109 (89–116) | 99 (89.5–106) | 0.003 |  > 0.9999 |  < 0.0001 |
GAF: median (IQR) | 88 (80–90) | 48 (40–68) | 43.5 (37.8–54.5) |  < 0.0001 | 0.9874 |  < 0.0001 |
Antipsychotic dose: CPZ mg median (range) | – | 200 (67–1000) | 200 (50–909) | – | 0.2879 | – |